NDC 0006-4094-01 - RECOMBIVAX HB
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 0006-4094
- Requested NDC
- 0006-4094-01
- Package NDCs from labels
- 0006-4094-01, 0006-4094-02
- Manufacturer
- Merck Sharp & Dohme LLC
- Effective date
- 2024-10-31
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| RECOMBIVAX HB - Merck Sharp & Dohme LLC | Merck Sharp & Dohme LLC | 2024-10-31 | VACCINE LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 0006-4094-01 | RECOMBIVAX HB | 1 mL in 1 SYRINGE | INJECTION, SUSPENSION | 1 | 32 | |
| 0006-4094-02 | RECOMBIVAX HB | 10 in 1 CARTON | INJECTION, SUSPENSION | 10 | 32 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 0006-4094-01 | ML - Milliliter | 0006-4094 | c25a9048-31c0-4d85-96d8-e7607da545a8 | 1 | 2014-08-01 |
| 0006-4094-02 | ML - Milliliter | 0006-4094 | 49491561-33fe-4edc-8516-315aed238ae3 | 1 | 2014-08-01 |
| 0006-4094-09 | ML - Milliliter | 0006-4094 | 81959c94-7e44-4807-9dec-426df875a254 | 1 | 2013-02-13 |
DailyMed Socrata Ingredients#
| Ingredient | Type | UNII | DailyMed label | SPL version | Uploaded |
|---|---|---|---|---|---|
| HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN | ACTIVE INGREDIENT | XL4HLC6JH6 | RECOMBIVAX HB (HEPATITIS B VACCINE (RECOMBINANT)) INJECTION, SUSPENSION [MERCK SHARP & DOHME CORP.] | 19 | |
| HEPATITIS B VIRUS SUBTYPE ADW HBSAG SURFACE PROTEIN ANTIGEN | ACTIVE MOIETY | XL4HLC6JH6 | RECOMBIVAX HB (HEPATITIS B VACCINE (RECOMBINANT)) INJECTION, SUSPENSION [MERCK SHARP & DOHME CORP.] | 19 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| INVANZ | ERTAPENEM SODIUM | Merck Sharp & Dohme LLC | 33f3b99b-fa82-42e0-26bf-f49891ae3d22 | 2026-02-04 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| VERQUVO | VERICIGUAT | Merck Sharp & Dohme LLC | 17056d73-1b1b-4bf2-9c07-b7a9367f0d6d | 2026-01-21 | Boxed warning, Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| PREVYMIS | LETERMOVIR | Merck Sharp & Dohme LLC | 1b49df80-be4f-47e0-a0b7-123f3e69395b | 2026-01-14 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| RECARBRIO | IMIPENEM ANHYDROUS, CILASTATIN, AND RELEBACTAM ANHYDROUS | Merck Sharp & Dohme LLC | be32f468-738b-40df-a425-591e12f65159 | 2025-12-09 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ENFLONSIA | CLESROVIMAB | Merck Sharp & Dohme LLC | c9004a92-40e8-4cdb-b22d-d07929f8fc3b | 2025-06-20 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| BELSOMRA | SUVOREXANT | Merck Sharp & Dohme LLC | e5b72731-1acb-45b7-9c13-290ad12d3951 | 2025-03-10 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| JANUVIA | SITAGLIPTIN | Merck Sharp & Dohme LLC | f85a48d0-0407-4c50-b0fa-7673a160bf01 | 2024-11-14 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ZINPLAVA | BEZLOTOXUMAB | Merck Sharp & Dohme LLC | 8f479bfe-2bfa-4cc5-9aee-1357364480b0 | 2024-11-12 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ZOLINZA | VORINOSTAT | Merck Sharp & Dohme LLC | cd86ee78-2781-468b-930c-3c4677bcc092 | 2024-11-12 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| ISENTRESS | RALTEGRAVIR | Merck Sharp & Dohme LLC | 89a5ec53-d956-4329-8004-0f40f51c88a3 | 2024-10-18 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| Dificid | FIDAXOMICIN | Merck Sharp & Dohme LLC | dd966338-c820-4270-b704-09ef75fa3ceb | 2024-10-16 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| CANCIDAS | CASPOFUNGIN ACETATE | Merck Sharp & Dohme LLC | 3bad23a6-09a6-4194-9182-093ed61bc71c | 2024-10-11 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| STROMECTOL | IVERMECTIN | Merck Sharp & Dohme LLC | 681888c9-af79-4b7d-ae80-c3f4f6f1effd | 2024-09-20 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| PRIMAXIN IV | IMIPENEM AND CILASTATIN SODIUM | Merck Sharp & Dohme LLC | f41d8abd-7792-4918-1b93-bd83ea01955e | 2024-07-05 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
| EMEND | APREPITANT | Merck Sharp & Dohme LLC | 696f9e80-9cae-403b-de9e-078343ce4713 | 2024-07-05 | Warnings, Adverse reactions | Merck Sharp & Dohme LLC |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.